We are live on ! Find out more

INmune Bio

INMB

Market cap $44.7M

1.60 USD

+0.07

4.58%

At close Updated Oct 29, 4:00 PM EDT

1 day

4.58%

5 days

4.58%

1 month

-18.37%

3 months

-5.33%

6 months

20.3%

Year to date

3.9%

1 year

-12.09%

5 years

-91.3%

10 years

-79.97%

About: INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.

Employees: 21

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 13.3%

Neutral 86.7%

Negative 0%

INmune Bio Inc. to Report Third Quarter 2026 Financial Results and Provide Corporate Update on Thursday, November 5th

Management to host conference call and webcast at 4:30 pm ET on that day BOCA RATON, Fla, Oct. 29, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced t that it will host a conference call on Thursday, November 5th, 2026 at 4:30pm EDT to discuss results for its quarter ended September 30, 2026 and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.

INmune Bio Inc. to Report Third Quarter 2026 Financial Results and Provide Corporate Update on Thursday, November 5th

INmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private Placement

BOCA RATON, Fla., Oct. 28, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has entered into a definitive agreement with a single healthcare-focused, institutional investor for a registered direct offering of an aggregate of 3,000,000 shares of common stock and a concurrent private placement of unregistered warrants to purchase up to 3,000,000 shares common stock (together, the “Offering”).

INmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private Placement

INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027

BOCA RATON, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has submitted its final pre-Marketing Authorisation Application (pre-MAA) package to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Ebstrocel™ (CORDStrom™), its investigational cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). The company has updated its regulatory submission strategy, as faster-than-expected manufacturing progress supports a full MAA submission in early February 2027, with potential UK approval in mid-2027, subject to MHRA review.

INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027

INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar

Initial focus on named-patient access in selected European and MENA markets, providing a capital-efficient foundation for broader commercialization BOCA RATON, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has entered into a Master Services Agreement with Uniphar Durbin Ireland Limited (“Uniphar”) establishing a scalable framework to support international access, distribution and commercialization of Ebstrocel™, the Company's allogeneic stromal cell therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB).

INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar

INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™

Collaboration combines INmune Bio's clinical research with QCi's Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro Initial engagement marks QCi's first commercial customer in pharmaceutical and biotechnology markets, expanding the application of quantum computing to drug development BOCA RATON, Fla. and HOBOKEN, N.J.

INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™

INmune Bio to Attend the 2026 Maxim Growth Summit

BOCA RATON, FL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, is excited to announce its participation in the upcoming 2026 Maxim Growth Summit, taking place from October 12th to 14th at The Hard Rock Hotel NYC. This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries.

INmune Bio to Attend the 2026 Maxim Growth Summit

INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board

Appointments strengthen rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel™ advances toward potential commercialization BOCA RATON, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced the appointments of R.

INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board

INmune Bio to Present at the H.C. Wainwright Global Investment Conference

The on-demand presentation will be available on September 11, 2026, at 7:00 A.M. (ET) BOCA RATON, Fla, Sept.

INmune Bio to Present at the H.C. Wainwright Global Investment Conference

INmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory Alignment

INmune Bio is significantly undervalued, with Ebstrocel for RDEB driving a compelling investment thesis amid regulatory alignment and a $67M market cap. Ebstrocel offers systemic itch reduction, differentiating it from competitors like KRYS's Vyjuvek, and is positioned for UK, EU, and US regulatory filings by early 2027. Regulatory milestones may include upcoming filings for approval, and the initiation of a confirmatory Phase 3 trial.

INmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory Alignment

INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings

Orphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ in RDEB Filings support a planned EU MAA in Q1 2027; orphan designation, if granted and maintained through approval, may provide regulatory incentives and 10 years of market exclusivity

INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings

See News Rankings

Price charts implemented using Lightweight Charts™